From AI sceptic to cautious adopter, this blog cuts through the hype to explore where AI genuinely helps regulatory professionals—and where human judgement remains non‑negotiable.

We’re thrilled to spotlight two of Weatherden’s brightest minds in our latest #MeetTheExperts blog: Andy Grieve and Margaret Jones – Industry veterans and pioneers of Baysian and adaptive trial designs. 

Why you’ll want to read: 

• Get Andy’s take on overcoming resistance to Bayesian methods, and why the skeptics are now converts. 

• Learn Margaret’s playbook for designing nimble, data-driven development plans that flex to real-world results. 

• See concrete examples of how adaptive trials are changing the game for patients and sponsors alike. 

Despite significant advances in biology, chemistry, and drug development platforms, drug attrition rates have remained stagnant in recent years. Dr Duncan McHale, co-founder of Weatherden, explores some of the ways big pharma has tried to tackle this problem – and why they’ve largely fallen short.